Search
lisocabtagene maraleuce (BREYANZI)
Indications:
- treatment of adults with relapsed or refractory large B-cell lymphoma after multiple lines of systemic therapy, high-grade B-cell lymphoma, & follicular lymphoma grade 3B
Dosage:
- 50-110 106 CAR-positive viable T-cells (consisting of CD8 & CD4 components)
* cell suspension for infusion, 70000000 CELLS/ML [1]
Adverse effects:
- most common:
- fatigue, cytokine release syndrome, musculoskeletal pain, nausea, headache, encephalopathy, infections, anorexia, diarrhea, hypotension, tachycardia, dizziness, cough, constipation, abdominal pain, vomiting, edema
* boxed warning
- cytokine release storm
- neurotoxicity
Mechanism of action:
- CD19-directed genetically modified autologous T-cell immunotherapy
General
chimeric antigen-receptor (CAR) T-cell therapy; tisagenlecleucel; CTL019 (Kymriah)
References
- RxNorm
- Breyanzi prscribing information
https://packageinserts.bms.com/pi/pi_breyanzi.pdf